Deciphering the Anti-Tumor Mechanisms of Metformin Through Reprogramming of the Tumor Microenvironment
Cells · 29.06.2026 · 15 (13) · 1183
DOI: 10.3390/cells15131183 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 29.06.2026. Verfasst von Ting Zeng und 8 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Carcinogenesis, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South Universit…. Hauptthemen laut MEDLINE: Metformin, Tumor Microenvironment, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, scientific research plan project of Hunan Provincial Health Commission, Hunan Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Metformin is a cornerstone medication for type 2 diabetes and exhibits anti-tumor activities. Previous studies have demonstrated that metformin suppresses tumor progression by regulating multiple signaling pathways, including the AMPK, PI3K/AKT/mTOR, and JNK pathways. However, most previous studies have focused on its direct effects on tumor cells, with limited attention to its effects in the TME. The TME constitutes a multifaceted ecosystem that drives tumor development and therapeutic resistance via physical barrier formation, immune evasion, and abnormal angiogenesis. In this review, we systematically summarize the impact and underlying regulatory mechanisms of metformin on distinct components of the TME. In addition, we discuss the individual and combined roles of metformin in immunity and inflammation, as well as vascular, matrix, and metabolic regulation. By elucidating the mechanisms of metformin-mediated TME reprogramming, we aim to provide new perspectives for understanding its anti-tumor effects and facilitating its clinical translation in cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHC Key Laboratory of Carcinogenesis, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410078, China.
- Cancer Research Institute, Xiangya School of Basic Medical Sciences, Central South University, Changsha 410078, China.
- The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha 410078, China.
- Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
ORCID-Profile: Ming Zhou
Förderung
- National Natural Science Foundation of China
- scientific research plan project of Hunan Provincial Health Commission
- Hunan Provincial Natural Science Foundation of China
- program of Introducing Talents of Discipline to Universities
- Free Exploration Program of Central South University
Zitieren
APA
Zeng, T., Zheng, L., Wei, J., Xue, C., Wei, Q., Xin, H., Wu, Z., Zhou, M., & Li, M. (2026). Deciphering the Anti-Tumor Mechanisms of Metformin Through Reprogramming of the Tumor Microenvironment. Cells, 15(13), 1183. https://doi.org/10.3390/cells15131183
Vancouver
Zeng T, Zheng L, Wei J, Xue C, Wei Q, Xin H, et al. Deciphering the Anti-Tumor Mechanisms of Metformin Through Reprogramming of the Tumor Microenvironment. Cells. 2026;15(13):1183. doi:10.3390/cells15131183
BibTeX
@article{Zeng2026,
author = {Zeng, Ting and Zheng, Lemei and Wei, Jianxia and Xue, Changning and Wei, Qingqing and Xin, Huizhen and Wu, Zubing and Zhou, Ming and Li, Mengna},
title = {Deciphering the Anti-Tumor Mechanisms of Metformin Through Reprogramming of the Tumor Microenvironment},
journal = {Cells},
year = {2026},
volume = {15},
number = {13},
pages = {1183},
doi = {10.3390/cells15131183}
}
EUVIMED